H2 Receptor Antagonist

Phase 3Small molecule

H2 Receptor Antagonist is one of 148 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Esophageal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Active, not recruiting

Lung Neoplasm MalignantRecruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 3

Active, not recruiting

Lung Neoplasm MalignantPhase 2

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

H2 Receptor Antagonist

Merck & Co.

Phase 3

5 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Remeron

OOrganon and Co

Preclinical

1 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

REGN2810

Regeneron

Preclinical

1 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Patients With Solid Tumors

NCT06789172

Q2 2029

PreclinicalRecruiting

Esophageal Squamous Cell Carcinoma

NCT05319730

Q2 2030

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT06305754

Q1 2032

Phase 2Recruiting

Lung Neoplasm Malignant

NCT06788912

Clinical

Trials by Indication[1]

Patients With Solid Tumors1 trial

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Recruiting·EEpkin·Phase 1·NCT06789172·166 enrolled

Ovarian Cancer1 trial

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06824467·770 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06305754·520 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT05319730·230 enrolled

Lung Neoplasm Malignant1 trial

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06788912·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for H2 Receptor Antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — H2 Receptor Antagonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for H2 Receptor Antagonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

H2 Receptor Antagonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2029

Q2 2030

Q1 2032

Trials by Indication[1]

Patients With Solid Tumors1 trial

Ovarian Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

Esophageal Squamous Cell Carcinoma1 trial

Lung Neoplasm Malignant1 trial

References

Drug Info

Quick Facts

Related News